| Completed | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer Triple Negative Breast Cancer, Breast Cancer | Phase 2 | 2022-03-03 |
| Terminated | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer Triple Negative Breast Cancer | Phase 2 | 2021-12-08 |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy T Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult | Phase 2 | 2021-06-04 |
| Completed | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Nega TNBC - Triple-Negative Breast Cancer, Breast Cancer | Phase 3 | 2021-05-14 |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (N Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer | Phase 2 | 2021-04-30 |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity | Phase 3 | 2021-01-06 |
| Completed | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast C Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm | Phase 1 | 2018-05-09 |
| Completed | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2018-03-29 |
| Completed | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive Small Cell Lung Cancer | Phase 2 | 2017-06-29 |
| Terminated | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer | Phase 2 | 2017-02-02 |
| Unknown | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locall Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm | Phase 1 / Phase 2 | 2017-01-01 |
| Completed | First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2016-05-01 |
| Completed | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Small Cell Lung Cancer | Phase 1 / Phase 2 | 2015-10-05 |
| Completed | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Sma Small Cell Lung Cancer | Phase 1 / Phase 2 | 2015-06-26 |
| Completed | Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1 Healthy Volunteers | Phase 1 | 2014-09-01 |
| Approved For Marketing | Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer Myelosuppression Adult, Chemotherapeutic Toxicity, Small Cell Lung Cancer | — | — |